That “effective dose” from the rat study? Divide by 6.2, adjust for surface area—and understand why even that math is unreliable.

Related Guides

Quick Facts

What This Guide Covers

1. The intuitive approach and why it fails
2. The biology of metabolic scaling
3. Body surface area scaling and the human equivalent dose (HED)
4. A worked example with BPC-157
5. The limits of allometric scaling
6. The gap between allometric estimates and real clinical doses
7. What this means for self-experimentation communities
8. Frequently asked questions

↑ Back to top

The Intuitive Approach and Why It’s Wrong

The straightforward way to think about dose translation is linear body weight scaling. The math looks bulletproof:

• Rat weight: 250 g = 0.25 kg
• Rat dose: 10 mcg/kg
• Rat total dose: 10 mcg/kg × 0.25 kg = 2.5 mcg
• Human weight: 70 kg
• Human dose (by linear weight scaling): 10 mcg/kg × 70 kg = 700 mcg

This approach assumes that body weight is the only relevant variable—that if you give the same dose per kilogram to any animal, you get the same effect. If 10 mcg/kg works in a rat, 10 mcg/kg works in a human.

The assumption is intuitive. It also fails at the level of basic physiology.

Why linear weight scaling is wrong: the fundamental problem

A 250-gram rat does not have 280 times less need for a drug simply because it weighs 280 times less than a 70-kilogram human. The rat’s body is not a scaled-down human. The rat’s organs work harder, its cells turn over faster, its enzymes process drugs with greater intensity. When a rat receives a drug, that drug is cleared from its system faster—not just because the rat is smaller, but because the rat’s metabolic machinery runs hotter.

This becomes obvious when you think about basic metabolism. A rat at rest burns approximately 7 calories per kilogram of body weight per day. A human at rest burns approximately 1 calorie per kilogram of body weight per day. That is a 7-fold difference in metabolic rate per unit mass. A mouse is even more extreme—approximately 10 calories per kilogram per day, a 10-fold difference from humans.

This metabolic intensity has direct pharmacological consequences. The liver, kidneys, and other organs that metabolize and eliminate drugs do so proportional to metabolic rate. If a rat’s liver is running at 7 times the metabolic intensity of a human liver, the rat clears drugs roughly 7 times faster. A drug dose that maintains a certain blood concentration in a rat will be cleared too quickly to maintain that same concentration in a human if you use the same dose-per-kilogram.

In other words: linear weight-based scaling assumes the rat and the human have equivalent physiology per unit weight. They don’t. The rat is pharmacologically much hotter. To achieve equivalent drug exposure in both animals, you need to give the rat a higher dose per kilogram than the human—or equivalently, you need to give the human a lower dose per kilogram than the naive math suggests.

↑ Back to top

The Biology Behind the Problem: Allometry and Metabolic Rate

The relationship between body size and metabolic rate is one of the oldest problems in biology. It was formally described by Max Rubner in the 1880s and refined by the allometric power laws that biologists use today.

Kleiber’s Law is the canonical observation: whole-organism metabolic rate scales with body weight to the 3/4 power, not the 1st power. Mathematically: Metabolic Rate = K × (Body Weight)^0.75

This means that metabolic rate does not scale linearly with weight. A 10-fold increase in body weight produces only a 5.6-fold increase in metabolic rate (10^0.75 ≈ 5.6). When you account for this using body surface area (which scales with weight to the 2/3 power), the metabolic rate per unit of body surface area remains relatively constant across species of different sizes. This is Rubner’s Surface Law—the observation that most mammals have similar metabolic rates per unit of surface area.

Why this matters for drugs: The organs and tissues responsible for drug metabolism (the liver, kidneys, intestinal epithelium) scale with body surface area, not with body weight. If a rat’s metabolic rate is 7 times higher per kilogram than a human’s, that is because the rat’s surface area relative to its weight is much higher. The rat’s liver, per unit of surface area, processes drugs at roughly the same rate as a human liver per unit of surface area.

This insight—that surface area, not weight, is the pharmacologically relevant variable—forms the basis of the FDA-approved method for translating animal doses to human-equivalent doses.

↑ Back to top

Body Surface Area Scaling: The FDA Standard

The FDA and international regulatory agencies use allometric scaling to convert animal doses to human-equivalent doses. The standard reference is Reagan-Shaw et al. (FASEB Journal, 2008), which established the conversion method now used by the FDA’s Center for Drug Evaluation and Research.

The formula:

Human Equivalent Dose (HED) = Animal Dose × (Animal Km / Human Km)

Where Km is a scaling factor that captures the animal’s metabolic rate relative to body weight:

These Km values are derived from Meeh’s surface area formula and represent the metabolic intensity of each species relative to its body weight.

Worked example with realistic numbers:

A published rat study uses BPC-157 at 10 mcg/kg. The rat weighs 250 grams (0.25 kg).

1. Rat total dose: 10 mcg/kg × 0.25 kg = 2.5 mcg
2. Human-equivalent dose (using allometric scaling): 10 mcg/kg × (6 / 37) = 1.62 mcg/kg
3. For a 70 kg human: 1.62 mcg/kg × 70 kg = 113.4 mcg

Comparison:

• Naive weight-based scaling: 10 mcg/kg × 70 kg = 700 mcg
• Allometrically corrected: 113.4 mcg

The allometrically scaled dose is roughly 6 times lower than the naive calculation. This is not a small adjustment—it changes the estimated human dose by a full order of magnitude.

The mechanics: The ratio of Km values (6 to 37) captures the fact that a rat’s liver, kidney, and other drug-metabolizing organs are running at higher metabolic intensity. The Km for rats (6) is lower than the Km for humans (37), reflecting that rats are pharmacologically “hotter” and clear drugs faster. The conversion factor of 6/37 ≈ 0.16 incorporates this difference. When you apply this factor to the dose-per-kilogram value, you get a lower dose-per-kilogram for humans—which is the correct adjustment for the fact that human drug-metabolizing organs, per unit mass, are cooler and less active.

↑ Back to top

A Concrete Example: BPC-157

BPC-157 (Body Protection Compound-157) is useful for understanding this problem in practice because it has the most extensive rodent dosing data of any peptide compound in the community. Most published BPC-157 studies use rats or mice and report doses in the range of 1–100 mcg/kg, most commonly around 10 mcg/kg.

Scenario: A researcher reads a rat study showing that 10 mcg/kg BPC-157 accelerates tendon healing (a true finding from published literature). They want to estimate a plausible human dose.

Step 1: Naive approach

• Rat dose: 10 mcg/kg
• “For a 70 kg human, that’s 10 × 70 = 700 mcg”
• This number floats around community forums and vendor recommendations, and is widely accepted as a standard dose.

Step 2: Allometrically corrected approach

• Rat Km = 6, Human Km = 37
• Rat dose per kg: 10 mcg/kg
• Human-equivalent dose per kg: 10 × (6 / 37) = 1.62 mcg/kg
• For a 70 kg human: 1.62 × 70 = 113.4 mcg

The gap: The community dose (700 mcg) is roughly 6 times higher than the allometrically scaled estimate (113 mcg).

What does this gap mean? It does not automatically mean the community dose is wrong. But it does mean the community dose is substantially higher than what the rat pharmacology predicts should be necessary. The community dose is based on linear weight scaling, not allometric scaling. Whether that higher dose is justified by other factors (different route of administration, safety data from community use, etc.) is a separate question, addressed later in this guide.

↑ Back to top

The Limits of Allometric Scaling: What It Does and Doesn’t Account For

Allometric scaling is a powerful tool, but it is not magic. It corrects for differences in metabolic rate across species of different sizes. It does not correct for everything.

What allometric scaling accounts for:

• Differences in baseline metabolic rate (the reason you need lower doses in larger, slower-metabolizing animals)
• General pharmacokinetic scaling—the rate at which drugs are absorbed, distributed, and eliminated

What allometric scaling does NOT account for:

• Species-specific differences in drug metabolism. Humans and rats have different liver enzyme systems. Some compounds are metabolized preferentially by enzymes that are more active in rats than in humans, or vice versa. Allometric scaling assumes metabolic rate is the only relevant difference—it is not.
• Absorption differences. A drug administered subcutaneously in rats may be absorbed more or less efficiently than the same route in humans, independent of size.
• Distribution differences. The same drug might bind differently to human proteins than rat proteins, or distribute into different tissue compartments with different kinetics.
• Receptor density and affinity. The target receptor might be present at different densities in human vs. rat tissue, or have different binding affinities for the same ligand.
• Route of administration. Allometric scaling works best when the route is the same across species. Oral, IV, and subcutaneous routes have very different pharmacokinetics; scaling oral rat data to IV human dosing is fraught.

The honest interpretation: Allometric scaling gets you in the right ballpark. It corrects for the most obvious and largest source of difference between animals of different sizes—metabolic rate. But it is a rough approximation, not a law of nature. The real human dose for any compound is determined through Phase I dose-escalation studies in humans. Allometric scaling is useful for predicting what that Phase I starting dose should be, but it cannot predict the actual clinical dose without human data.

↑ Back to top

From Allometric Estimate to Clinical Dose: The Phase I Gap

Understanding the allometric scaling approach makes clear why published clinical doses often differ from allometric predictions.

The dose development pathway:

1. IND application (Investigational New Drug): The sponsor proposes a starting dose for human testing, based on allometric scaling from animal data. The FDA reviews this and may request modifications.

1. Phase I dose escalation (humans): Small groups of healthy subjects receive doses starting at the allometrically predicted level and escalating stepwise. The goals are safety, tolerability, and pharmacokinetics. Phase I determines the maximum tolerated dose and the relationship between dose and blood levels.

1. Phase II efficacy studies (humans with the target disease): Uses dose levels informed by Phase I to explore whether the compound actually works in the disease population. This is where the clinically active dose is discovered.

1. Phase III confirmation (pivotal trials): Tests the Phase II dose in a larger population to confirm efficacy and safety.

For most community-used peptides, the data stops at step 1 or 2. There are no Phase I or Phase II studies. This is the central challenge: allometric scaling is a tool for predicting Phase I starting doses, but without Phase I data, we don’t know whether that prediction is correct.

Example: BPC-157

• Preclinical data: Dozens of rat and mouse studies, doses typically 1–100 mcg/kg, usually 10 mcg/kg, showing efficacy in various injury models.
• Allometric prediction for Phase I starting dose: Roughly 1.5–2 mcg/kg (using Reagan-Shaw conversion).
• Actual human data: Three published human studies (two for inflammatory bowel disease, one for distal radial fracture). None were randomized controlled trials. Doses ranged from 2.4 mg once daily (roughly 30 mcg/kg for a 70 kg person) to 100 mg daily (roughly 1,400 mcg/kg). These doses are substantially higher than the allometric prediction—and even higher than the naive linear scaling prediction.

Why the discrepancy? Several possible explanations:

• Oral BPC-157 may have poor bioavailability, necessitating higher doses to achieve adequate blood levels.
• The injectable and oral formulations used in community protocols may use different excipients and have different absorption kinetics.
• The human studies were small, open-label, and may not reflect the doses that would have been used if regulatory rigor had been applied.

The point: allometric scaling and actual clinical dosing can diverge. The allometric dose is a useful anchor, but it is not the final answer.

↑ Back to top

What This Means for Self-Experimentation Communities

Most dosing protocols used in self-experimentation communities for preclinical-only compounds are not derived from allometric scaling. They are derived from three sources:

1. Naive weight-based scaling from rodent studies. “The rat dose is 10 mcg/kg, so the human dose is 10 mcg/kg”—this is the most common derivation.

1. Vendor recommendations. Peptide suppliers often provide dosing suggestions, which sometimes reference rat data and sometimes are based on vendor experience or folklore.

1. Community trial-and-error. Users share experiences, report outcomes, and iteratively adjust dosing based on perceived effects and side effects.

These three sources can overlap and reinforce each other, but they are distinct from evidence-based allometric scaling.

Why this matters:

If a community dose is derived from naive weight-based scaling, it is likely 3–10 times higher than the allometrically scaled estimate. This does not automatically mean the community dose is wrong or dangerous. Peptidings makes no judgment about the absolute safety of higher doses. But it means the community dose is based on a pharmacologically incorrect assumption, and the dose is higher than what the preclinical data suggests is necessary.

The honest assessment:

Some community doses may be justified. If higher doses are used because:

• The route of administration (e.g., subcutaneous) has poor bioavailability, and higher doses are needed to achieve adequate blood levels
• Decades of anecdotal community use suggests that higher doses are safe and more effective
• The compound is used for an indication different from the preclinical studies, requiring dose adjustment

… then the higher dose is defensible on grounds other than the preclinical data.

Other community doses may be unjustifiably high. Without human pharmacokinetic data, without bioavailability studies in the actual route of administration, and without Phase I dose escalation in humans, the distinction is impossible to make with certainty.

What allometric scaling IS useful for:

Allometric scaling is useful as a sanity check. If a community protocol uses a dose that is 20–100 times higher than the allometrically scaled estimate, the protocol is pharmacologically implausible, even accounting for differences in route, formulation, and bioavailability. If the community dose is within 1–10 times the allometric estimate, the dose is at least in a ballpark that might be justified by factors other than the preclinical data.

↑ Back to top

The Honest Conclusion

Allometric scaling is a useful tool for translating animal doses to estimated human-equivalent doses. It accounts for the fundamental difference in metabolic rate across animal sizes and produces estimates that are FDA-approved starting points for Phase I dose escalation.

But allometric scaling cannot establish the “correct” human dose for a compound that has never been tested in humans. The actual human dose—the dose that balances efficacy, safety, and tolerability in the target population—is determined through Phase I and Phase II studies. For compounds in the preclinical-only tier (which describes most peptides currently used in self-experimentation communities), that testing has not occurred.

This creates a gap between what the preclinical data predicts (via allometric scaling) and what anyone using the compound actually knows about human dosing. In that gap sits a choice: whether to follow the preclinical prediction, follow community consensus, follow vendor suggestions, or attempt your own dose finding.

Allometric scaling does not resolve that choice. What it does is give you the tool to evaluate whether a particular choice is pharmacologically plausible. If a dose is 6 times higher than the allometric estimate, that is a fact worth knowing—not because the higher dose is necessarily wrong, but because it reflects an assumption (linear weight-based scaling, or some other factor) that deserves to be examined.

The straight-talk assessment: Allometric scaling is one of the most useful tools for understanding peptide dosing. It is also one of the most commonly ignored, partly because the linear weight-based approach is more intuitive and partly because community consensus often converges on higher doses. Know the method. Understand what your community dose actually is in relation to the allometric estimate. Then make your decision with that knowledge in hand.

↑ Back to top

Frequently Asked Questions

Related Guides

• Drug Development in Humans: From Phase I to Approval
• How to Read a Preclinical Study
• Biomarker Testing for Peptide Users
• BPC-157: Evidence, Dosing, and the Human-Rodent Gap

↑ Back to top

Summary and Key Takeaways

The core problem: Linear weight-based scaling from animal studies assumes that metabolic rate scales linearly with body weight. It doesn’t. Smaller animals have higher metabolic rates per unit mass and clear drugs faster. Linear scaling systematically overstates the human dose needed.

The FDA solution: Allometric scaling using body surface area (Reagan-Shaw et al., 2008) corrects for differences in metabolic rate across species. For rats to humans, the correction factor is approximately 0.16 (Km ratio of 6 to 37). A rat dose of 10 mcg/kg translates to an allometrically scaled human dose of roughly 1.6 mcg/kg—about 6 times lower than naive weight-based scaling.

What this means for actual peptides: Most community dosing protocols are derived from linear weight-based scaling, not allometric scaling. The community doses for compounds like BPC-157 are typically 3–10 times higher than the allometric prediction. This does not automatically mean they are wrong, but it means they are based on a pharmacologically incorrect assumption about how doses scale.

What allometric scaling does and doesn’t do: It accounts for differences in metabolic rate—the largest and most fundamental difference between animal sizes. It does not account for species-specific differences in drug metabolism, absorption, distribution, or receptor function. It is useful for understanding what the preclinical data predicts, but it cannot establish the “correct” human dose for a compound that has never been tested in humans.

The honest application: Allometric scaling is a tool for sanity-checking whether a community dose is in a pharmacologically plausible range. It is not a prescription. The actual human dose for any compound is determined through human studies. Until those studies exist, allometric scaling—combined with an honest assessment of what we do not know—is the best tool available.

↑ Back to top

Disclaimer

This guide is provided for educational and research purposes only. It explains the scientific method for translating animal doses to human-equivalent doses and does not constitute medical advice or a recommendation to use any compound at any dose. The translation from animal studies to human dosing involves uncertainty and should not be treated as a substitute for clinical guidance from a qualified healthcare provider. Consult a healthcare provider before making any decisions about peptide use.

↑ Back to top

Selected References and Key Studies

Primary Reference for Allometric Scaling:

Reagan-Shaw S, Nihal M, Ahmad N. “Dose translation from animal to human studies revisited.” FASEB Journal. 2008;22(3):659-661. This is the seminal paper establishing the Km-based allometric scaling method used by the FDA for dose translation. It provides the scientific justification for the approach and the specific Km values used in this guide.

Foundational Metabolic Scaling Biology:

Kleiber M. “Body size and metabolism.” Hilgardia. 1932;6(11):315-353. The foundational work establishing that metabolic rate scales with body weight to the 3/4 power, not the 1st power.

FDA Guidance:

FDA Center for Drug Evaluation and Research. “Guidance for Industry: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adults, Healthy Volunteers.” 2005. While not specific to allometric scaling, this guidance document describes the FDA’s approach to using animal data to establish human starting doses.

↑ Back to top

Further Reading

For readers wanting to deepen understanding of pharmacokinetics and dose translation:

• Mahmood I. “Prediction of drug clearance in humans from animal models: A comparative evaluation of physiologically based pharmacokinetic models.” Journal of Pharmaceutical Sciences. 2016;105(9):2908-2916.
• Nair AB, Jacob S. “A simple practice guide for dose conversion between animals and human.” Journal of Basic and Clinical Pharmacy. 2016;7(2):27-31.
• Guidance on Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. ICH Technical Guidelines. The International Council for Harmonisation provides guidance on translating animal data to human trials for biological compounds, including peptides.

↑ Back to top

Additional Notes for the Editorial Team

Structure and voice: This draft follows the straight-talk approach by giving the preclinical data honest credit (allometric scaling is real and important) while being explicit about what it does and doesn’t do. It does not moralize about community doses or claim they are wrong—it simply provides the tool to understand the gap. It serves Marcus (the self-directed researcher) through the worked examples and plain English callouts; serves Dr. Priya through the mechanistic detail and citations; and serves Jake through the BLUF and the direct, non-hedging tone throughout.

Tone calibration: The guide avoids marketing language and academic hedging equally. It doesn’t say “the evidence remains limited”—it specifies that Phase I and Phase II studies are what are needed. It doesn’t oversell allometric scaling as perfect—it lists the specific factors it does and doesn’t account for.

Citation confidence: Reagan-Shaw et al. 2008 is the standard reference for this method and appears in FDA guidance. The Km values (mouse 3, rat 6, human 37) are directly from FDA guidance documents and the Reagan-Shaw paper. The BPC-157 examples reflect real dosing from published studies and community reports.

Remaining questions for editorial review: Should this guide include a section on how to calculate allometric scaling by hand, or is the walkthrough sufficient? Should there be a table comparing naive vs. allometric scaling for a range of common rat doses? (Both seem reasonable additions, but are outside the core scope.) The FAQ is structured to anticipate the most common reader questions based on community usage patterns.

—

↑ Back to top

---